|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.
|
|
2
|
American Thoracic Society; Infectious
Diseases Society of America. Guidelines for the management of
adults with hospital-acquired, ventilator-associated, and
healthcare-associated pneumonia. Am J Respir Crit Care Med.
171:388–416. 2005.
|
|
3
|
Hirota S, Isozaki K, Moriyama Y, et al:
Gain-of-function mutations of c-kit in human gastrointestinal
stromal tumors. Science. 279:577–580. 1998.
|
|
4
|
Thiel G, Ekici M and Rössler OG:
Regulation of cellular proliferation, differentiation and cell
death by activated Raf. Cell Commun Signal. 7:82009.
|
|
5
|
Mirsadraee M, Oswal D, Alizade Y, et al:
The 7th lung cancer TNM classification and staging system: Review
of the changes and implications. World J Radiol. 4:128–134.
2012.
|
|
6
|
Lei B, Liu S, Qi W, et al: PBK/TOPK
expression in non-small-cell lung cancer: its correlation and
prognostic significance with Ki67 and p53 expression.
Histopathology. 63:696–703. 2013.
|
|
7
|
Erler BS, Presby MM, Finch M, et al:
CD117, Ki-67, and p53 predict survival in neuroendocrine
carcinomas, but not within the subgroup of small cell lung
carcinoma. Tumour Biol. 32:107–111. 2011.
|
|
8
|
Mohammad T, Garratt J, Torlakovic E, Gilks
B and Churg A: Utility of a CEA, CD15, calretinin, and CK5/6 panel
for distinguishing between mesotheliomas and pulmonary
adenocarcinomas in clinical practice. Am J Surg Pathol.
36:1503–1508. 2012.
|
|
9
|
Cheng D, Kong H and Li Y: Prognostic
values of VEGF and IL-8 in malignant pleural effusion in patients
with lung cancer. Biomarkers. 18:386–390. 2013.
|
|
10
|
Chatterjee S, Heukamp LC, Siobal M, et al:
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis
in lung cancer. J Clin Invest. 123:1732–1740. 2013.
|
|
11
|
Yang Y, Li J, Mao S and Zhu H: Comparison
of immunohistology using pan-CK and EMA in the diagnosis of lymph
node metastasis of gastric cancer, particularly micrometastasis and
isolated tumor cells. Oncol Lett. 5:768–772. 2013.
|
|
12
|
Kanapathy Pillai SK, Tay A, Nair S and
Leong CO: Triple-negative breast cancer is associated with EGFR,
CK5/6 and c-KIT expression in Malaysian women. BMC Clin Pathol.
12:182012.
|
|
13
|
Al-Dubai SA, Qureshi AM, Saif-Ali R,
Ganasegeran K, Alwan MR and Hadi JI: Awareness and knowledge of
breast cancer and mammography among a group of Malaysian women in
Shah Alam. Asian Pac J Cancer Prev. 12:2531–2538. 2011.
|
|
14
|
Casali C, Stefani A, Rossi G, et al: The
prognostic role of c-kit protein expression in resected large cell
neuroendocrine carcinoma of the lung. Ann Thorac Surg. 77:247–253.
2004.
|
|
15
|
Boldrini L, Ursino S, Gisfredi S, et al:
Expression and mutational status of c-kit in small-cell lung
cancer: prognostic relevance. Clin Cancer Res. 10:4101–4108.
2004.
|
|
16
|
López-Martin A, Ballestín C,
Garcia-Carbonero R, et al: Prognostic value of KIT expression in
small cell lung cancer. Lung Cancer. 56:405–413. 2007.
|
|
17
|
Yoo J, Kim CH, Song SH, et al: Expression
of c-kit and p53 in non-small cell lung cancers. Cancer Res Treat.
36:167–172. 2004.
|
|
18
|
Tsao MS, Sakurada A, Cutz JC, et al:
Erlotinib in lung cancer - molecular and clinical predictors of
outcome. N Engl J Med. 353:133–144. 2005.
|
|
19
|
Hirsch FR, Herbst RS, Olsen C, et al:
Increased EGFR gene copy number detected by fluorescent in situ
hybridization predicts outcome in non-small-cell lung cancer
patients treated with cetuximab and chemotherapy. J Clin Oncol.
26:3351–3357. 2008.
|
|
20
|
Park EA, Lee HJ, Kim YT, et al: EGFR gene
copy number in adenocarcinoma of the lung by FISH analysis:
investigation of significantly related factors on CT, FDG-PET, and
histopathology. Lung Cancer. 64:179–186. 2009.
|
|
21
|
Dy GK, Miller AA, Mandrekar SJ, et al: A
phase II trial of imatinib (ST1571) in patients with c-kit
expressing relapsed small-cell lung cancer: a CALGB and NCCTG
study. Ann Oncol. 16:1811–1816. 2005.
|
|
22
|
Schneider BJ, Kalemkerian GP, Ramnath N,
et al: Phase II trial of imatinib maintenance therapy after
irinotecan and cisplatin in patients with c-Kit-positive,
extensive-stage small-cell lung cancer. Clin Lung Cancer.
11:223–227. 2010.
|
